Afatinib in Patients with Advanced HER2 Mutation-Positive (M plus ) NSCLC Previously Treated with Chemotherapy

被引：0
|
作者：
Zhou, Caicun [1 ]
Fan, Yun [2 ]
Wang, Huijuan [3 ]
Liam, Chong Kin [4 ]
Hu, Chengjie [5 ]
Cseh, Agnieszka [6 ]
机构：
[1] Shanghai Pulm Hosp, Med Oncol, Shanghai, Peoples R China
[2] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Internal Med, Zhengzhou, Henan, Peoples R China
[4] Univ Malaya Med Ctr, Dept Med, Kuala Lumpur, Malaysia
[5] Boehringer Ingelheim China Investment Co Ltd, Beijing, Peoples R China
[6] Boehringer Ingelheim Rcv GmbH & Co KG, Dept Med Affairs, Vienna, Austria
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
NSCLC; afatinib; HER2; phase II;
D O I：
10.1016/j.jtho.2016.11.1506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-013
引用
收藏
页码：S1077 / S1077
页数：1
相关论文
共 50 条
  • [31] TREATMENTS FOR EGFR MUTATION-POSITIVE (M plus ) NSCLC PATIENTS - A NETWORK META-ANALYSIS (NMA) BY MUTATION TYPE
    Popat, S.
    Yang, J. C. H.
    Lungershausen, J.
    Griebsch, I
    Marten, A.
    Wu, Y. L.
    VALUE IN HEALTH, 2014, 17 (07) : A615 - A615
  • [32] Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC
    Ruiter, G.
    Tu, H. -Y.
    Ahn, M. -J.
    Yoh, K.
    Zugazagoitia, J.
    Smit, E.
    Wu, Y. -L.
    Planchard, D.
    Cho, B. -C.
    Wehler, B.
    Zhao, Y.
    von Wangenheim, U.
    Rohrbacher, M.
    Sadrolhefazi, B.
    Lin, G.
    Yu, Y.
    Nadal, E.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S4 - S5
  • [33] Trastuzumab emtansine in patients (pts) with HER2 mutation-positive (HER2mut) tumors: TAPISTRY study
    Kim, Jeong Eun
    Thomas, David
    Gadgeel, Shirish
    Corassa, Marcelo
    Tan, Tira J.
    Girda, Eugenia
    Richards, Donald
    Tejpar, Sabine
    Chen, David
    Fang, Junhan
    Patel, Sid
    Wilson, Timothy R.
    Barlesi, Fabrice
    CANCER RESEARCH, 2024, 84 (07)
  • [34] Afatinib in patients with EGFR mutation-positive (EGFRm plus ) NSCLC harbouring uncommon mutations: Experience in 'Real-World' clinical practice
    Maerten, Angela
    Brueckl, Wolfgang
    Laack, Eckhart
    Hoffmann, Christopher
    Zhou, Caicun
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 160
  • [35] Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Major Uncommon Mutations
    Yang, J. Chih-Hsin
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S31 - S31
  • [36] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Dickgreber, Nicolas J.
    Halmos, Balazs
    Hirsh, Vera
    Hochmair, Maximilian J.
    Levy, Benjamin Philip
    De Marinis, Filippo
    Mok, Tony
    O'Byrne, Kenneth
    Okamoto, Isamu
    Schuler, Martin H.
    Sebastian, Martin
    Shah, Riyaz N. H.
    Tan, Eng-Huat
    Yamamoto, Nobuyuki
    Marten, Angela
    Massey, Dan
    Wind, Sven
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    Passaro, A.
    Yang, J. C.
    Ahn, M.
    Dickgreber, N. J.
    Halmos, B.
    Hirsh, V.
    Hochmair, M. J.
    Levy, B. P.
    de Marinis, F.
    Mok, T.
    O'Byrne, K.
    Okamoto, I.
    Schuler, M.
    Sebastian, M.
    Shah, R.
    Tan, E.
    Yamamoto, N.
    Maerten, A.
    Wind, S.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2015, 26 : 77 - 77
  • [38] Afatinib in EGFR Mutation-Positive NSCLC: Activity in Patients with Brain Metastases, and Impact on CNS Progression/Spread
    O'Byrne, K.
    Yang, J. C.
    Wu, Y.
    Hirsh, V.
    Yamamoto, N.
    Popat, S.
    Tamiya, A.
    Maerten, A.
    Schuler, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S855 - S855
  • [39] ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC
    Mao, Shiqi
    Zhou, Fei
    Liu, Yiwei
    Yang, Shuo
    Chen, Bin
    Xu, Jian
    Wu, Fengying
    Li, Xuefei
    Zhao, Chao
    Wang, Wanying
    Liu, Qian
    Yu, Xiaofei
    Jia, Keyi
    Shao, Chuchu
    Zhou, Caicun
    Gao, Guanghui
    Ren, Shengxiang
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (01) : 219 - 228
  • [40] ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC
    Shiqi Mao
    Fei Zhou
    Yiwei Liu
    Shuo Yang
    Bin Chen
    Jian Xu
    Fengying Wu
    Xuefei Li
    Chao Zhao
    Wanying Wang
    Qian Liu
    Xiaofei Yu
    Keyi Jia
    Chuchu Shao
    Caicun Zhou
    Guanghui Gao
    Shengxiang Ren
    Cancer Immunology, Immunotherapy, 2022, 71 : 219 - 228
12345